Fig. 7: Resistance of synthetic SARS-CoV-2 variants to broadly neutralizing antibodies.
From: Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
a BA.5 and synthetic SARS-CoV-2 receptor-binding domain (RBD) variants. Red: substitutions in BA.2 RBD relative to Wuhan-Hu-1; magenta: substitutions BA.5 RBD relative to BA2. Highlighted in green are substitutions in the synthetic variants, chosen based on antibody selection experiments. b Inhibition of synthetic variants by broadly neutralizing antibodies. Relative infection was calculated as a decimal fraction of infection measured (with 1 µg/ml antibody) relative to an uninhibited virus control (without antibody). A median of two independent experiments is shown. c Fold inhibition of natural and synthetic variant infection by individual broadly neutralizing antibodies. Individual data points represent the median of two independent experiments for n = 40 individual antibodies. Red line = group median fold inhibition for all antibodies tested.
